{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:35:26Z","timestamp":1794270926627,"version":"4.9.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.esmoop.2024.102961","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T22:25:57Z","timestamp":1713479157000},"page":"102961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":false,"given":"J.","family":"Rodon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2476-5732","authenticated-orcid":false,"given":"M.L.","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.Y.-C.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Socinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7571-2385","authenticated-orcid":false,"given":"J.D.","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-366X","authenticated-orcid":false,"given":"J.S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Al Baghdadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.-M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Golmakani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.N.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gazdoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.W.","family":"Tolcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmoop.2024.102961_bib1","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond","volume":"72","author":"Stopa","year":"2015","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102961_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-21-0620","article-title":"SAM-competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance","volume":"21","author":"Jensen-Pergakes","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102961_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrc.2016.51","article-title":"RNA splicing factors as oncoproteins and tumour suppressors","volume":"16","author":"Dvinge","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102961_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.celrep.2018.01.088","article-title":"Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types","volume":"23","author":"Seiler","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.esmoop.2024.102961_bib5","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.2021.39.15_suppl.3019","article-title":"PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or meta-static solid tumors: a phase 1 dose escalation study","volume":"39","author":"Rodon","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102961_bib6","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/psp4.12882","article-title":"PK\/PD model-informed dose selection for oncology phase I expansion: case study based on PF-06939999, a PRMT5 inhibitor","volume":"12","author":"Guo","year":"2023","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102961_bib7","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-18-3276","article-title":"PDK1 mediates NOTCH1-mutated head and neck squamous carcinoma vulnerability to therapeutic PI3K\/mTOR inhibition","volume":"25","author":"Sambandam","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102961_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1158\/1541-7786.MCR-20-0565","article-title":"CYLD alterations in the tumorigenesis and progression of human papillomavirus-associated head and neck cancers","volume":"19","author":"Cui","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102961_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102961_bib10","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102961_bib11","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A\u00a0natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2024.102961_bib12","doi-asserted-by":"crossref","first-page":"v159","DOI":"10.1093\/annonc\/mdz244","article-title":"METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours","volume":"30","author":"Siu","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.102961_bib13","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1182\/blood-2021-146987","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes","volume":"138","author":"Haque","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.esmoop.2024.102961_bib14","doi-asserted-by":"crossref","first-page":"S462","DOI":"10.1016\/j.annonc.2020.08.651","article-title":"First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers","volume":"31","author":"Villar","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102961_bib15","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1038\/s41598-021-86834-7","article-title":"Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression","volume":"11","author":"Busacca","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102961_bib16","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102961_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ccell.2019.05.014","article-title":"Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss","volume":"36","author":"Fedoriw","year":"2019","journal-title":"Cancer Cell"},{"issue":"6278","key":"10.1016\/j.esmoop.2024.102961_bib18","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924007294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T15:35:36Z","timestamp":1717342536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924007294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2059702924007294"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102961","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102961"}}